3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
35
Lymphoma
10
Leukemia, B-Cell
10
Leukemia
9
Recurrence
8
Lymphoma, Non-Hodgkin
7
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Follicular
6
Neoplasms
5
Bronchiolitis Obliterans Syndrome
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Mantle-Cell
3
Lymphoma, B-Cell
2
Hodgkin Disease
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Thrombocytopenia
1
Paraproteinemias
1
Oncology Patients Receiving Chemotherapy
1
Melanoma
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphocytosis
1
Lymphadenopathy
1
Leukemia, Prolymphocytic
1
Leukemia, Lymphoid
1
Fever
1
Fatigue
1
Disease
1
Agammaglobulinemia
1
Interventions
ofatumumab
1
ocrelizumab
1
obinutuzumab
1
ibritumomab tiuxetan
1
Rituximab
1
Paclitaxel
1
Diphenhydramine
1
Cetirizine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Oncology Patients Receiving Chemotherapy
×
ofatumumab
×
Clear all
NCT04189588
2023-10-06
versus
TerSera Therapeutics LLC
Phase 2
Completed
34 enrolled
11 charts